Scbio

Developer of small molecule immuno-oncology drugs

placeYuseong, Daejeon, South Korea calendar_todayFounded 2021 groups23 employees language sc-bio.co.kr

Innovation

4 patent families (1 granted) — focus: Human necessities; filing pace active. Cited 19 times.

YearFilings
20254

Investor mix

13 investors on record.

Investor typeCountShare
Venture capital646%
Private equity323%
Accelerator & incubator18%
Bank & private debt18%
Other / undisclosed215%
Coming soon